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presented at the Catholic Medical Association 73rd Annual Meeting, 
2004. 
And it came to pass, that, when Elisabeth heard the salutation of 
Mary, the babe leaped in her womb; and Elisabeth was filled with the 
Holy Ghost: 
And she spake out with a loud voice and said, "Blessed art thou 
among women and blessed is the fruit of thy womb. 
"And whence is this to me, that the mother of my Lord should come 
to me? 
"For, 10, as soon as the voice of thy salutation sounded in mine ears, 
the babe leaped in my womb for joy." • 
-Luke 1:41-44' 
Introduction 
Elisabeth and Mary bear witness in the fIrst chapter of the gospel of 
Luke to the overwhelming evidence, available for many centuries, of the 
humanity of the fetus. The very idea that a baby in utero will respond to 
external stimuli no longer remains in doubt. Parents rush out to buy 
Mozart, Bach, and other "brain-building" music thought to enhance the 
prenatal development and future intellectual development of their preborn 
little one.2 The purpose of this paper will entail the meshing of our 
Christian faith with the latest in care of the preborn baby: the unseen 
human in our care. 
The paper will address the fetus as our patient by addressing fIve 
areas: basic Christian ethical framework for the discussion, Christian 
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medical history, a brief description of fact-value distinction, the medical 
development of the fetus as our patient, and a description of care of the 
terminal perinate. 
Basic Christian Ethics 
This paper does not suppose to be an exhaustive discussion of moral 
theology or the Bible. The paper approaches the Bible and the elaboration 
of the Christian ethic from the perspective of Cornelius Van Til and his 
ethic of presuppositions.3 Van Til argued that the presuppositions or basic 
beliefs brought to scripture will drive the interpretation and application of 
Biblical truth. Thus, this paper presupposes that: God's word is inerrant 
(without error as written), God does exist as His word says He does, He is 
present and operational in our everyday lives, and that His word is clear 
enough for us to understand and formulate a Biblical ethic. The Bible 
addresses the pre-delivery personality of the unborn child, 
Psalm 139: 14 "I will praise thee; for I am fearfully and wonderfully 
made: marvelous are they works; and that my soul knoweth right 
well" 
Luke 1 :39-41 "And it carne to pass that, when Elisabeth heard the 
salutation of Mary, the babe leaped in her womb;'" 
From these two brief examples in scripture, the humanity of the 
unborn are affirmed and the basis for the ethical treatment of babies 
validated. 
Christian Medical History 
Science has been described as "thinking God's thoughts after him". 
From the earliest days of its inception, Christianity took a great interest in 
the physical human body since Christ deigned to come in the flesh to dwell 
amongst men (John 1:14-15).1 
Numerous examples in history demonstrate the profound influence 
of Christianity on medicine and give us a proud heritage to emulate. A few 
salient examples follow. The first is "Fabiola of the Fabians" (c 395 A.D.). 
Fabiola was a wealthy Roman matron of the patrician Fabian family, 
burdened with a profligate husband. She established the first Western 
hospital in Rome.4 She was an avid patron and supporter of Jerome 
(translator of Scriptures from Greek to Latin Vulgate Bible) Jerome wrote 
of Fabiola, 
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First of all she founded an infirmary and gathered into it sufferers 
from the streets, giving their poor bodies worn with sickness and 
hunger all a nurse's care . . . How often did she carryon her own 
shoulders poor filthy wretches tortured by epilepsy. How often did 
she wash away the purulent matter from wounds which others would 
not even endure to ' look upon! She gave food with her own hand, and 
even when a man was but a breathing corpse, she would moisten his 
lips with drops of water ... Rome was not large enough for her 
compassionate kindness. She went from island to island and traveled 
round the Etruscan Sea, and through the Volscian province, with its 
lonely curving bays, where bands of monks have taken up their 
home, bestowing her bounty either in person or by the agency of men 
of holy faith 5 
Her efforts led to the establishment of one of the first hospices ever 
known in Portus, Italy in roughly 395 A.D. This hospice was so successful 
that it became famous from Parthia (the Eastern Roman empire) to Britain 
(the Western Roman empire) for its loving care of dying patients. 
Edward Jenner (1749-1823), the conqueror of smallpox, possessed a 
vital faith. He spent over 20 years investigating the linkage between 
cowpox and smallpox. Jenner found that milkmaids infected with 
smallpox did not become ill with smallpox. His final test included Phipps, 
a young boy with cowpox, waiting two months and then infecting him with 
smallpox. The boy proved immune to smallpox, definitively proving that 
vaccination would prevent a disease (smallpox). He noted about God (with 
regard to smallpox), "I do not wonder that men are grateful to me, but 1 am 
surprised that they do not feel gratitude to God for thus making me a 
medium of good." (my emphasis)5 Thomas Hodgkin (1798-1866) was a 
devout Quaker and discoverer of Hodgkin's Lymphoma.' His kindness, 
charity, and lack of recognition marked his life.5 He died in Jaffa of 
dysentery while on a mission to assist persecuted Jews in the Holy Land.5 
James Young Simpson (1811-1870) discovered chloroform for anesthesia! 
child-birth as part of his never-ending search for improved methods of 
accomplishing surgery.5 His tenacity of purpose, coupled with his great 
faith, allowed Simpson to become successful. Simpson provided millions 
of women and patients a freedom from the pain of childbirth and surgery. 
Joseph Lister (1827-1912), the originator of antiseptic surgery, blended his 
devout faith with his keen scientific mind to save thousands of lives by 
perfecting surgical techniques to decrease infections from operations. 
Lister made the observation of the Christian physician's task, "It is our 
proud office to tend the fleshly tabernacle of the immortal spirit, and our 
path, if rightly followed, will be guided by unfettered truth and love 
unfeigned."5 
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Fact-Value Distinction 
The process of the growth of science led to a "fact-value" distinction 
in society. The belief became dominant that the only things knowable were 
scientific and since moral values were not scientific, they were not 
knowable. As the explosive growth of science began in the Renaissance, it 
continued into the Enlightenment and promptly "lost" God. In the 
Enlightenment, autonomous man became the measure of all things. 
Religious faith was denigrated and made somehow incongruous with 
science. Thus, there was made a "fact-value distinction" in that which is 
knowable, is science, and that which is moral, is not knowable and relative. 
The philosophy took root that only science is repeatable, observable, and 
knowable. 
However; it is known that specific moral actions (i.e. sexual 
promiscuity resulting in venereal disease/cervical dysplasia for women) 
will lead to celtain outcomes much as jumping off a bridge leads to gravity 
taking you down to meet the water (science). 
Coupled with this new moral relativism came the onslaught of 
Darwin 's theory of evolution regarding the origin of man. Darwin, in his 
hatred of God, needed to remove the divine from the scientific realm. His 
clever answer was to remove God from science. To validate evolution, 
Darwin postulated a series of random events over eons of time causing 
multiple evolutionary changes and resulting in "man the accident". 
Unfortunately, scientists like Darwin and the higher critics had it all wrong. 
Organisms did not evolve and life is not random. It is now known that life 
is "irreducibly complex", necessitating the simultaneous appearance of 
multiple organs, biochemical pathways, and processes at precisely the 
appropriate time. This complexity may be demonstrated in just a few 
examples: 
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a) Problem of the eye: How and why would such an organ develop? 
All the elements must appear at the same time, including the 
necessary biochemical reactions present in the rods/cones to make us 
"see" as well as neural pathways in brain. The pathways need to be 
intact with the neurochemicals in the brain matter itself to transmit 
the inverted images to the frontal lobes, which would then "know" 
how to invert the image so it is "right-side" up! 
b) Closer to the fetal world would be the formation of a placenta 
with the literally hundreds of chemicallhormonal/receptor 
interactions necessary to support a human life. All of these 
pathways, hormones, and biochemical cascades must be present from 
the beginning, able to follow in a complex order in the proper 
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sequence, and not miss a step, or we see a miscarriage or fetal 
malformation. 
c) Embryologically, the formation of a single fetal heart outstrips the 
most fantastic science fiction ever written. The choreography of the 
folding, bending, rotating of the fetal heart all takes place almost 
before the mother knows she is with child (about 5 weeks from the 
first day of the last menstrual cycle). 
Development of the Fetus as Our Second Patient 
There have been fantastic advances in human embryology since the 
19th century. Scientific inquiry discovered how the human fetus grew from 
a single cell into the complete baby ready for delivery. The moral theory of 
personhood from the scripture in Psalm 139 dovetails with scientific 
theory. As the Psalmist notes in verses 139: 14-16, 
" ... for I am fearfully and wonderfully made: marvelous are thy 
works; and that my soul knoweth right well. My substance was not 
hid from thee, when I was made in secret, and curiously wrought in 
the lowest parts of the earth. Thine eyes did see my substance, yet 
being unperfect; and in thy book all my members were written, 
which in continuance were fashioned, when as yet there was none of 
them.' 
The discovery by the deeply pious, Christian physician Dr. Jerome 
Lejeune in 1959 of the etiology of Trisomy 21, or Down Syndrome, as an 
extra chromosome 21 signaled the birth of modem genetics. Dr. Lejeune 
was the first physician to characterize an abnormal ' chromosomal 
complement as the etiology for a specific syndrome: Trisomy 21 as the 
source of the diagnosis of Down syndrome. Unfortunately, due to Dr. 
Lejeune's outspoken pro-life views and passion for children with 
chromosomal defects, he was denied a Nobel Prize in medicine for his 
ground-breaking discovery. 
The advent and progress of diagnostic obstetrical ultrasound over the 
last 30 years gives us a fantastic window to the womb. Ultrasound 
depiction of fetal anatomy replicates the embryological development of the 
human fetus almost exactly as previous gross pathologic studies had 
discovered. The most recent real-time 3D/4D ultrasounds now produce 
scans so life-like and human-like that no one can mistake them for 
anything but a baby. Once again, the Biblical view is vindicated as science 
follows scripture. 
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The technological advances in therapies for newborns have 
accelerated from relatively modest beginnings to very sophisticated and 
high technology therapies. These developments have led to the new 
science of invasive "in utero therapy". All of these new therapies owe their 
impetus to the creative genius of Dr. (Sir) William Liley (1929-1983). He 
is truly the "father of modem in utero therapy" with his discovery of in 
utero blood transfusions for hemolytic Rh disease in the fetus. Dr. Liley 
knew the Rh affected neonate was severely anemic at birth. He reasoned 
he could use packed red cells to transfuse a premature anemic Rh positive 
affected fetus in utero much as an anemic adult would be transfused. Dr. 
Liley began by transfusing radioactively tagged 0 negative red cells into 
the fetal abdomen in 1963.6 Liley chose the radioactively tagged red cells 
so fluoroscopy could be used to guide placement of the packed cells into 
the fetal abdomen since obstetrical ultrasound was not yet available. 
In Utero Anomalies Amenable to Therapy 
The list of in utero anomalies that are amenable to therapy has risen 
steadily since Dr. Liley's first transfusions. One of the major triumphs of 
in utero therapies has been the advent of vitamin therapy with the addition 
of extra folic acid to the diet of women to prevent NTDs or to decrease the 
recurrence of NTDs in patients with either a previously affected child or 
family history of neural tube defects (NTD). This simple vitamin therapy 
has decreased the recurrence risk of NTD in a previously affected woman 
by more than 70%.7 In utero therapy is now available for multiple 
conditions. They include: bladder outlet obstructions, immune or 
infectious hydrops, diaphragmatic hernia, fetal immunity (SCIDS) defects, 
neural tube defects, fetal teratomas, fetal cardiac arrhythmias, and fetal 
cardiac anomalies. 
Bladder outlet obstruction results usually from incomplete 
cannulization between the pelvic and distal urogenital sinus. The 
incidence is 1/5000-1/8000 male fetuses and the babies usually die from 
pulmonary hypoplasia secondary to incomplete lung development with 
anhydrarnnios. Fetal urinalysis provides prognostic projections of 
anticipated neonatal outcomes. 
The fetal bladder is sampled via an amniocentesis needle. Using the 
values in the table below results in a good prognosis: 
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Urine sodium < 100 MeqlliterB 
Urine chloride < 90MeqlliterB 
Urine osmolality < 200 milliosmolliterB 
Beta-2 microglobulin < 4 mglliter9 
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The algorithm for evaluation for possible fetal bladder shunt 
placement requires three sequential urine samples 48-72 hours apart.1O 
After ascertainment of the fetal bladder urine with good prognosis 
biochemical results, a double pig-tail vesicoamniotic shunt to drain the 
bladder is placed. The placement of the shunt does not necessarily solve 
the possible problem of renal dysplasia that may follow the therapy. The 
shunt does, however, allow amniotic fluid to accumulate and prevents 
pulmonary hypoplasia with relatively normal lung function. There is still a 
33-50% risk of renal failure in childhood after shunting. I I Some researchers 
believe there is a possible role for renal biopsy of the fetus prior to shunt 
placement to look for histologic evidence of intact renal function. 
The next triumph of science came in treating immune hydrops for Rh 
sensitization. The incidence of Rh negative blood in the various ethnic 
groups is 15% caucasian of European descent, 8% African-Americans, 8% 
Hispanics from Mexico/Central America, and <1 % in Eskimo, Native 
American, Chinese, and Japanese descent. 
Prior to the advent of Rhogam the rate of Rh sensitization was 43 .3/ 
1000 samples in 1967 and dropped to 2.6/1000 samples in 1996 after Rh 
immune globulin injections at 28 weeks and post-partum.1 2 The 
management of Rh disease involves testing for Rh antibody titers and 
looking for a critical titer of at least 1: 16 or a 4-fold rise from base (i.e from 
1:8 to 1 :32). The maternal titers are tested monthly and must be done at the 
same laboratory for consistency and to prevent variation. Part of the 
antepartum testing involves paternal Rh status and zygosity testing. New 
advances allow us to check the father of the baby for possible Rh negative 
gene status. If the father of the baby is heterozygous (one Rh negative 
gene) , it is possible to do fetal Rh typing on an amniocentesis sample with 
a 98+% accuracyl3 and fetal RhD testing on the fetal DNA in maternal 
serum with virtually 100% accuracy.14 An RhD negative fetus would 
require no further antepartum follow up or testing. 
In the recent past (5 years), serial amniocentesis would be performed 
for titers beginning at approximately 18-22 weeks and use the Liley curves 
for determining if a fetus was at risk for being affected. Liley developed 
the curves using the delta optical density or OD450 for hemoglobin 
breakdown to assess how much fetal blood was being hemolyzed. The 
OD450 values would reflect fetal status in utero with regard to anemia. 
The Liley curves use 3 simple zones based on delta OD450 compared to 
gestational age to determine critical values. 
If the fetus was found to be in a critical range on the delta OD450 
curve, a fetal cord blood sampling at the cord insertion site with a 22 gauge 
spinal needle would be done to determine if the hematocrit was less than 
30% or 2 standard deviations below mean for the gestational age. An 
opening hematocrit is obtained, and if anemic, the fetus transfused to a 
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hematocrit of 35-40%. The transfused RBCs degrade their hematocrit 
about 1 %/day, so, multiple intravascular transfusion procedures are often 
necessary. Most sensitized babies deliver between 35-37 weeks with the 
last transfusions at 30-32 weeks. IS Transfusions for a hematocrit < 30% 
may be done as early as 18 weeks. 
Doppler ultrasound is now used at less than 35 weeks with the 
measurement of a peak middle cerebral artery velocity (MCA) to determine 
the need for cord sampling or delivery. It is over 98% accurate at > 1.5 
MoM (multiples of median for gestational age) for predicting fetal 
anemia. 16 The MCA also seems to be accurate for clinical management for 
the non-Rh isoimmune disorders of Kell, Kidd, or Duffy isoimmunization. 17 
Infectious etiologies related to fetal hydrops include the two most 
common etiologies: toxoplasmosis and Parvo-BI9. Toxoplasmosis is a 
protozoan parasite that is commonly found in cat feces as a result of 
exposure to rodents who carry the disorder or by eating poorly cooked red 
meat. Seroconversion in toxoplasmosis may take 1-4 months and carries a 
risk of infection in fetus of 15% in the fIrst trimester, 25% in the second 
trimester and 65% in the third trimester.18 Diagnosis of toxoplasmosis is 
by maternal blood testing for immune globulins: IgM (acute infection) and 
IgG (previous infection). Generally serial titers are performed 6-8 weeks 
apart to determine if there is a four-fold rise in titers. Fetal infection may 
be documented with the obstetrical ultrasound fIndings of: hydrops, 
cerebral calcifIcations, and liver calcifIcations. Diagnosis in the fetus may 
be done with amniocentesis with DNA-PCR on amniotic fluid (specifIcity 
of 95% and sensitivity-64%) to demonstrate evidence of infection.19 
Treatment in utero for toxoplasmosis with antibiotics (spectinimcyin and 
sulfa) has been successful in at least one case of fetal infectious hydrops.2o 
Parvo-Bl9 infection as a cause of non-immun~ hydrops is more 
common than thought and has been seen in 10-15% of previously 
undiagnosed cases of infectious hydrops.21, 22 Viral transmission rate to the 
fetus is about 30% and risk for fetal death, if infected, is 5-10% ,21, 22 
Therefore, the risk of death for the fetus is < 1 %.21. 22 The fetus most likely 
develops hydrops as a result of suppression of bone marrow red cell 
production by the virus or possibly due to fetal viral myocarditis.23 
Diagnosis is made by a positive IgM titer (acute infection) in maternal 
serum. The fetus is followed with serial weekly ultrasounds for 8-12 
weeks after acute infection to rule out hydrops and evidence of failure. If 
the ultrasound demonstrates hydropic changes, evidence of failure (ascites 
or pleural/pericardial effusions), or increased Dopplers (MCA), it will 
necessitate fetal cord blood sampling and possible intravascular 
transfusion (IVT) via the umbilical cord. Data shows that fetal IVT 
survival after hydrops diagnosis is over 84% where observational survival 
for hydrops was only 70%.24 
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Diaphragmatic hernia affects roughly in 1-4.5/1 0,000 live births and 
affects males/females equally. Left side hernias comprise 75-90% of 
hernias, right side hernias are 10%, and bilateral hernias are less than 5%.25 
The etiology is unknown but failure of closure of the pleuroperitoneal 
canals in the fetal abdominothoracic cavity is thought to be the cause. 
Hernias are diagnosed in the antepartum most commonly by ultrasound 
with a fluid collection in fetal chest. Fetal mortality in unselected cases is 
about 80%.26 Prognosis for the fetal survival postpartum is related to: large 
size, diagnosis at < 24 weeks , liver above diaphragm (liver above the 
diaphragm survival 43%IECMO 53 % and liver below the diaphragm 
survival 93%IECMO 19%), small contralateral lung, associated anomalies, 
and bilateral hernias. 27 Originally, open repairs in utero were attempted 
with varied success. Hernias with the liver above the diaphragm often 
"kinked" the umbilical/portal vein when the hernia was reduced and the 
abdominal contents pushed from the chest. There is an ongoing NIH trial 
at the University of San Francisco to try fetoscopic tracheal occlusion. A 
videofetoscopic technique is used to occlude the fetal trachea with a clip. 
The theory is to occlude the trachea to make the lung grow and gradually 
push the abdominal contents out of the chest back into the abdomen. To 
remove the clip at term, they use ex-utero intrapartum treatment (EXIT) 
procedure to partially deliver baby head/neck by c-section, the tracheal clip 
is identified by its string and removed, and the fetus intubated prior to 
delivery.28 The success rates in the 8 fetuses treated so far are 75 % success 
rates versus traditional surgery post-delivery.29 
A further attempt to treat congenital diaphragmatic hernias (CDH) 
involves the use of general or combined spinal-epidural anesthesia with 
fetal position for access of the neck to place a balloon into the fetal 
trachea. 3D A flexible Teflon cannula containing a pyramidal trocar is used 
to enter the amniotic cavity through the maternal abdomen. The cannula is 
directed to the fetal mouth and the trocar is removed. Fetoscopic 
instruments are placed with a sheath loaded with the fiber endoscope and a 
catheter loaded with a detachable gold valve balloon. A side port is used 
for arnnioinfusion with Hartmann solution. The endoscope is passed 
through the vocal cords to the trachea and the catheter is positioned to 
place the balloon above the vocal cords. The balloon is then inflated with 
isotonic Omniscan, a magnetic resonance imaging contrast agent. The 
balloon is removed at approximately 34 weeks either by fetal tracheoscopy 
or by puncturing the balloon with an ultrasound-guided needle. 3D A recent 
study involved 21 consecutive cases with occlusion. The lungs all became 
more echogenic within 48 hours and the lung area-to-head ratio improved 
from a median of 0.7 to 1.8 within 2 weeks. Nine of the twenty-one 
newborn infants died from complications of pulmonary hypoplasia. Ten of 
the 12 infants having surgical repair of CDH were doing well post-surgery 
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for a median of 18 months. Survival rates went from 30% in the first 10 
cases done in the third trimester to 64% in the next 11 cases done in the 
second trimester. The control group without balloon surgery had only 1 of 
11 infants survive to discharge. 3D 
The congenital cystic adenomatoid malformation (CCAM) is a 
hamartomatous pulmonary lesion seen on ultrasound as a cystic mass. 
They usually are unilateral, may involve either lung and any lobe, but 
usually are isolated to one lobe or segment oflung in about 95% of cases.3J 
CCAM's are bilateral in < 2% cases.3J There are three types of CCAM: 
macrocystic (cysts 2-10 cm-60% include medium cysts), medium size 
cysts (cysts < 2 cm), and microcystic (cysts < 0.5 cm-40%). 32 
The lesions may appear as solid or mixed cystic/solid tumors on 
ultrasound. Usually CCAM's are diagnosed at 16-22 weeks and most 
regress by third trimester (100% fetuses with regression survive). 33 Fetal 
hydrops is a very poor prognostic sign (100% mortality if treated 
expectantly).34 Mediastinal shift is an indication to attempt to tap a large 
mass in utero and may even result in the placement of an indwelling double 
pig-tail catheter. Some fetuses with large masses and hydrops may need to 
have in utero resection with an open surgical procedure (61 % survival 
compared to 100% mortality with expectant management).33 
Severe Combined Immunodeficiency Syndrome (SCIDS) may be 
inherited as an X-linked recessive, autosomal recessive, or even as a 
sporadic form. 35 It consists of the absence of both B-cell and T-cell 
immunity. These are the so-called "bubble children" who have been kept 
alive in a totally sterile environment within a plastic bubble room. If not 
kept in such a sterile environment, death comes to the neonate in the 
postpartum period by overwhelming viral or bacterial infection, usually 
within one year's time. The etiology of the disease is thought to be due to 
failure of hematopoietic stem cells to differentiate into the Band T 
lymphocytes.35 The fetus affected with SCIDS is immune incompetent and 
therefore able to be transfused with maternal stem cells without having a 
graft-versus-host rejection (the healthy fetus is immune competent by 14 
weeks).35 Therapy consists of taking maternal stem cells from maternal 
bone marrow and infusing the cells via the fetal umbilical cord with an IVT 
into the fetus at approximately 18+ weeks.35 The infant is born as a chimera 
with a mixture of maternal and fetal T and B lymphocytic cells with 
immune competence and normal ability to fight infection.35 New 
developments in the stem therapy story may even allow for in utero therapy 
of complex protein disorders like muscular dystrophy. Muscular 
dystrophies (MD) are a group of congenital disorders notable for 
progressive muscle degeneration and fibrosis. The defect in many of the 
MDs are either in the dystrophin or other proteins in the dystrophin-
associated protein (DAP) complexes. MDs are characterized by 
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progressive muscle destruction with focal regeneration with fibrosis in the 
affected muscles. This leads to a depletion of the satellite (muscle stem 
cells) with death as the result of muscle failure.36 The use of postnatal 
cellular therapy of MDs has been dismal due to the immunological reaction 
to allogenic donor cells and to dystrophin itself.37 The use of myogenic 
stem cells has the ability to overcome all the problems with postnatal 
cellular therapy. The early gestational period is the only time in 
development or life that large numbers of stem cells migrate to seed tissue 
compartments. The relative size of the fetus would allow for large scale 
transplantation of doses of stems that would not be possible in the postnatal 
period. Further, the exciting new developments of manipulating fetal 
tolerance to allow donor-specific or protein specific transplantation make 
therapies for MD a new reality?8 The normal myogenic stem cells would 
migrate to the muscles and thereby prevent the progressive degeneration of 
the muscles seen in classic MD. 
Neural tube defects (NTD) occur in roughly 111000 pregnancies 
and are related to folic acid deficiency, often as a result of the genetic 
defect in handling of folic acid in the tetrahydrofolate reductase pathway. 
The CDC noted in a 1992 study that supplementation of women without 
risk factors for NTDs with a multivitamin with 400 micrograms of folic 
acid at least one month prior to conception and continuing through the first 
trimester decreased the NTD rate by 50%.39 A more recent article by 
Evans, et aI., 2004, notes at least a 30+% decrease in NTDs in the general 
population of women in the United States without risk factors for NTDs 
with folic acid fortification of food stuffs.40 With a previously affected 
infant or first degree relative with an NTD (sibling/parent) patients need 4 
mg/day preconceptually for at least a month prior to pregnancy and 
continuing through the first trimester.41 This therapy reslUts in a greater 
than 70% reduction in the recurrence of NTDs in this at-risk patient 
population.41 Diagnosis of an NTD is most often made by an elevated 
screening maternal serum alphafetoprotein (MSAFP.) Neural tube defects 
may be seen on obstetrical ultrasound with the classic signs: "Lemon sign" 
with collapse of cerebral hemispheres to appear lemon-like, a dilated 
posterior fossa with Chiari II malformation, and/or an open neural defect in 
the spine 
The recommendation used to be made to abort these babies. Now, 
however, there is an exciting new in utero surgery for these babies' defects. 
There is a National Institute of Child Health and Human Development 
(NIHCD) study for surgery for NTDs. It is the Management of 
Myelomeningocele Study or "MOMS" study. 
The study involves 200 total women with 100 pregnancies randomized 
into either of two groups: in utero surgery or routine obstetrical follow up. 
Three centers are participating: Children's Hospital of Philadelphia, PA; 
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University of California, San Francisco, CA; and Vanderbilt University 
Medical Center, Nashville, TN. The inclusion criteria are: 
Highest lesion T1 through S 1 
Hindbrain herniation (Chiari II malformation) by MRI 
Maternal age 18 or older 
Gestational age 19 0/7 to 25 5/7 weeks for randomization 
The major exclusion criteria are: 
Non-resident of US 
Multifetal pregnancy 
Obesity with BMI > 35 
Abnormal karyotype or other anomalies 
Current or planned cerclage, incompetent or short cervix 
documented preterm labor, placenta previa or abruption 
History of spontaneous preterm birth < 37 weeks 
Maternal HIV/AlDS, Hepatitis B or C 
Uterine anomaly or contradiction to surgery or anesthesia 
Unable to travel or make follow-up at 12 and 30 months 
Information for enrollment into the study is found at: 
www.spinabifidamoms.com 
1-866-275-6667 (or 1-866-ASK-MOMS) 
Teratomas (sacral/pharyngeal) are the most coffifnon tumor of fetus 
and neonate.42 The incidence is 1140,000 births and malignant invasion is 
rare.42 These tumors are thought to arise from the primitive knot (Hensen's 
node) or caudal cell mass that has escaped normal inductive influences.43 
Unfortunately, fetal mortality is due to high-output shunting with 
heart failure and hydrops with placentomegaly. These tumors may also 
produce the "mirror syndrome" with maternal findings that mimic severe 
preeclampsia with elevated blood pressure, abnormal laboratory, and 
significant maternal edema.44 
These tumors may be diagnosed as early as 14 weeks by obstetrical 
ultrasound.45 They are seen as a distal caudal or intra-abdominal mass. 
Teratomas may look cystic, solid, or mixed in appearance on ultrasound. 
The differential diagnosis of this mass on ultrasound includes renal tumors, 
ovarian tumors, or myelomeningocele.46 Obstetrical Doppler flow 
ultrasound will assist in documenting effects of shunting in the baby.42 
There will be evidence of high flow in the lesion as well as high 
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outflow rates in the fetal heart. There may even be elevated fetal 
umbilical cord and middle cerebral artery Dopplers. Careful 
antepartum monitoring is necessary and there may need to be in utero 
intervention if heart failure develops. The newest technique for therapy 
involves ablation of feeder vessels with a radiofrequency ablation 
probe through a laparoscopic in utero method.47 The small numbers so 
far (5 cases) appear to demonstrate that this new technique is superior 
to surgical resection.47 
The twin-twin transfusion syndrome (TITS Syndrome) is most 
commonly a problem with monochorionic (shared placenta) twins with an 
incidence 10-20% of monochorionic twins.48 The syndrome is defined in 
the twins as : a growth discordance of 50%+, a marked difference in 
amniotic fluid (polyhydramnios and anhydramnios with a "stuck twin"), 
and divergent fetal hematocrits at birth (anemic "donor twin" and 
polycythemic "recipient twin").48 The major etiology for TTTS is thought 
to be shunting with vascular anastamoses between the twins with a "pump-
donor" twin and a "recipient" twin.48 The smaller donor twin often has 
severe oligohydramnios to anhydramnios with growth restriction while the 
recipient twin has polyhydramnios and hydrops from volume overload. 
The obstetrical ultrasound findings include: 
Monochorionic twins 
50% discordance 
Severe oligohydramnios donor ("stuck twin") 
Polyhydramnios in recipient 
Unequal placental sharing 
Arteriovenous communication by Doppler 
Favorable prognosticators (after Callen, Ultrasonography in Obstetrics 
& Gynecology, 4th edition, 2000, pg 776)49: 
Late-onset growth differences 
Late-onset polyhydramnios 
No hydrops 
No placentomegaly 
No cardiac failure 
Unfavorable prognosticators (after Callen, Ultrasonography in 
Obstetrics & Gynecology, 4th edition, 2000, pg 776)49: 
Early-onset growth differences «20-22 weeks) 
Early-onset polyhydramnios 
Hydrops 
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Placentomegaly 
Fetal cardiac failure 
The workup of the TTTS Syndrome include: chromosomes for both twins, 
detailed anatomic surveys (including fetal echocardiography) for 
associated anomalies, and detection of vascular anastamoses. 
Therapies may include: 
Serial amnio-reductions 
Creation of window between membranes 
Aggressive oral protein supplementation ("protein shakes") 
therapy for severe hypoproteinemia 
Fetoscopic laser ablation of communicating anastomosis: 
Dr. Julian De Lia of Milwaukee reports 153 total cases. 
Latest 67 cases from De Lia show: 
Mean gestational age 21 weeks (range 18-24.5 
weeks) 
55/67 (82%) one survivor and 94/134 babies 
surviving 
37 with surviving twins/18 one twin survivorll2 
none 
4/93 (4.3%) with significant handicap with mean 
follow up of 60 months (range 48-84 months)50 
For further information contact: 
TTTS Foundation: 
National Office 
Longbeach Parkway 
Bay Village, Ohio 44140 
Voice: 440-899-TTTS 
Fax: 440-899-1184 
Website: www.tttsfoundation.org 
Centers for referral include: 
202 
Dr. Julian De Lia, M.D. (creator oflaser therapy) 
St Joseph Regional Medical Center 
5000 West Chambers Street 
Milwaukee, Wl 53210-1688 
Phone: 414-447-3535 
Fax: 414-874-4506 
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Dr. Rubin Quintero, M.D. 
Florida Institute for Fetal Diagnosis and Therapy 
13601 Bruce B. Downs Blvd, Suite 160 
Tampa, FL 33613 
Phone: 888-338-2577 
Fax: 813-872-3794 
Fetal arrhythmias include tachyarrthymias which are 8% of fetal 
rhythm disorders.s' Tachyarrthymias are treated before 32-34 weeks, but if 
they occur after 32-34 weeks delivery is indicated. Before 32-34 weeks 
most physicians utilize maternal oral first line therapy of either first line: 
digoxin or flecainide; second line: oral therapy; Veraparnil, procainamide, 
quinidine, and propanolol; or with intravenous therapy with infusion of 
adenosine via the umbilical cord to break tachycardia with possible loading 
therapy with digoxin after conversion to a sinus rhythm. 52 
Bradyarrhthymias are seen in about 6% of fetal arrhythmia cases.53 
Bradyarrhthymias are common with structural defects (53 %), have 
ventricular rates < 55 bpm , and require pacemakers post-delivery. 53 With 
bradyarrhthymias a check of maternal serum for possible Sjogren 
Syndrome A (SSA) or Sjogren Syndrome B (SSB) antibodies is indicated. 
The SSA or SSB antibodies attack the fetal conduction system in the heart, 
causing a heart block. If the SSA or SSB antibodies are present, maternal 
therapy with oral steroids might be indicated. 
Hypoplastic left heart syndrome (lll..HS) is usually the result of 
aortic/mitral dysplasia or aortic/mitral atresia. It is most often inherited as 
an autosomal recessive. The recurrence risk with one child is 4% and with 
two children is 25%. The ultrasound shows a small left ventricle with 
generally an absent or small mitral valve and/or aortic valve. The 
prognosis may be poor with a very small left ventricle. Therapies include: 
Norwood in usually 3 stages to re-construct left ventricle 
Fontan to connect left atrium to tricuspid and right atrium to 
pulmonary artery 
In utero therapy is the latest attempt to treat this disorder. It involves 
a videolaparoscopic procedure to place a catheter into the fetus to perform 
a fetal valvuloplasty to open the mitral or aortic valve. Once the mitral or 
aortic valve is opened, the blood flow will allow the left ventricle to grow 
normally and perhaps allow for either less complex or no surgical repair. 54 
Balloon dilation of severe aortic stenosis in the fetus: potential for 
prevention of hypoplastic left heart syndrome: candidate selection, 
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technique, and results of successful intervention.55 It is still too early to tell 
if this treatment will become the treatment of choice for HLHS. 
Perinatal Hospice 
Woven throughout this exciting science of in utero therapy resonates the 
concept that we have two patients. However, what therapy could be offered 
to those families with terminally ill babies? What could be done to provide 
care for terminally ill perinates? Many patients do not desire termination 
of pregnancy no matter what the anomalies or prognosis.56 The proper 
response is to tum to "The Perinatal Hospice" which demonstrates 
ongoing care for the family and their baby, not abandonment. "Perinatal 
Hospice" is "Prenatal diagnosis of the terminally ill fetus in utero leading 
to perinatal hospice as part of the continuation of end of life care" .57 
The "Perinatal Hospice" addresses the major concerns of patients 
and family which are: abandonment, fear, and pain for baby and mother. 
The "Perinatal Hospice" allows compassion, not abandonment, and 
enables physicians to fulfull our faith while utilizing our reason/science to 
expand our ability to care ethically for our patients. 
Hospice uses a decision algorithm based on accurate prenatal 
diagnosis . (See Figure 1, page 205) Sophisticated obstetrical diagnostic 
ultrasound is utilized as well as amniocentesis for chromosomes and other 
related disorders . Only terminally ill fetuses with CONFIRMED diagnosis 
are included in hospice care. The staff involved in care include perinatal! 
neonatal staffs, residentslMFM Fellows/students, ultrasonographers 
(RDMS), nursing services (L&D/anteparturnlpostpartum), social services, 
hospital chaplains/local pastors, and grief counseling. 
As of December, 2004, Rockford Memorial HcJspital (RMH) has 
provided care for 28 families meeting the criteria for participation in this 
"Perinatal Hospice" as part of the care in a community based perinatal 
referral center. A significant majority of these patients 21128 (75%) have 
chosen the hospice alternative over early pregnancy termination. The 
seven pregnancy terminations consisted of fetuses with anencephaly (5 
patients), trisomy 18, and triploidy. In the remaining patients, 5/21 (24%) 
had an intrauterine fetal demise and 16/21 (76%) delivered live born 
infants. All patients who experienced an intrauterine fetal demise had a 
vaginal delivery. Of the live born infants, there were 15 vaginal deliveries, 
four were pre term and eleven were at term. Obstetric indication or 
maternal request resulted in cesarean delivery for 1121 (4%) at term. This 
cesarean section was performed for a child with acrania. The live born 
infants died within 20 minutes to 256 days after delivery. There were no 
maternal morbidities or mortalities. Hospice is safe for mother and of 
infinite value to the parents and family. 
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Figure 1 
Sample Decision Algorithm 
Anomaly Noted 
LethalAno4 TeL.tio~ Non-Lethal 
1 1 
Perinatal Hospice Prenatal Care 
1 1 
Non-aggressive Therapy Aggressive Care 
suppoL ~entiOniSl 
(No medications, (Allows IV fluids, 
heroic measures) considers minor interventions, 1 i.e., dosme of hem; •. etc.) 
Includes supportive care, 
allowing infant to die with 
family, medical care 
August, 2005 
Full care with 
surgery, intubation 
ICU care 
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In closing, let us consider the words of Thomas Sydenham (1624-
1689) the "English Hippocrates," 
It becomes every person who purposes to give himself to the care of 
others, seriously to consider the four following things: First, that he 
must one day give an account to the Supreme Judge of all the lives 
entrusted to his care. Second, that all his skill and knowledge and 
energy, as they have been given him by God, so they should be 
exercized for His glory and the good of mankind, and not for mere 
gain or ambition. Third, and not more beautifully than truly, let him 
reflect that he has undertaken the care of no mean creature; for, in 
order that he may estimate the value, the greatness of the human race, 
the only begotten Son of God became himself a man, and thus 
enobled it with His divine dignity, and far more than this, died to 
redeem it. And fourth, that the doctor being himself a mortal being, 
should be diligent and tender in relieving his suffering patients, 
inasmuch as he himself must one day be a like sufferer. 
SOLI DEO GLORIA (To God Alone be the Glory)! 
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